No, kidney transplantation is not a cure for IgA nephropathy (IgAN)
IgAN frequently recurs after kidney transplantation, with a cumulative recurrence rate of approximately 23% at 15 years post-transplant, and recurrence is associated with a 3.7-fold increased risk of graft loss 1. This makes transplantation a treatment for kidney failure caused by IgAN, not a cure for the underlying disease itself.
Why Transplantation Is Not Curative
The fundamental issue is that IgAN is a systemic immunologic disorder that persists even after the native kidneys are removed. The pathogenic process—involving abnormally glycosylated IgA1 molecules and immune complex formation—continues in the recipient's circulation and can deposit in the transplanted kidney 2.
Recurrence Rates and Timing
- Post-transplant IgAN recurrence approaches 15% at 10 years and increases to 23% by 15 years 3, 1
- Recurrence can occur from 6 months to over 10 years post-transplant 4
- When recurrence occurs, 32% of grafts are lost within 8 years of recurrence diagnosis 1
- Importantly, 100% of patients with documented recurrence progressed to graft failure in some series 4
Risk Factors for Recurrence
The 2010 KDIGO guideline recommends screening transplant recipients with IgAN for microhematuria at baseline, every 3 months during the first year, and annually thereafter 5. Specific risk factors that increase recurrence likelihood include:
Pre-transplant factors:
- Pre-emptive transplantation (hazard ratio 3.45) 1
- Younger recipient age 6
- Shorter time from IgAN diagnosis to kidney failure 6
- Related living donor transplantation 6
Post-transplant factors:
- Development of de novo donor-specific antibodies (hazard ratio 6.65) 1
- Preformed donor-specific antibodies (hazard ratio 2.59) 1
- Absence of induction immunosuppression 4
Clinical Implications
Monitoring Strategy
Based on guideline recommendations 5, transplant recipients with IgAN require:
- Monthly monitoring for the first 3 months for proteinuria and hematuria
- Every 3 months during the first year
- Annual screening thereafter
- Allograft biopsy when screening suggests recurrence or with unexplained graft dysfunction
Management of Recurrent Disease
The 2026 scoping review highlights that management strategies are heterogeneous and often extrapolated from native IgAN treatment 7. Current approaches include:
First-line interventions:
- Renin-angiotensin system blockade (most commonly used and associated with benefit) 7
- Blood pressure control to target <120/70 mmHg 8
- SGLT2 inhibitors 8
Additional considerations:
- The 2025 KDIGO guideline emphasizes that newer disease-specific treatments targeting pathogenic IgA should be considered 8, 9
- Tonsillectomy has shown benefit in Japanese cohorts but requires validation in other populations 7, 6
- Rituximab and emerging therapies (iptacopan, budesonide, telitacicept) warrant prospective trials 7
Pre-Transplant Optimization
Complete elimination of monoclonal protein before transplantation is critical when IgAN is complicated by monoclonal gammopathy, as demonstrated by successful 6-year follow-up after clone-directed treatment 10. This underscores that addressing the underlying immunologic abnormality—not just replacing the kidney—is essential for optimal outcomes.
Common Pitfalls
- Assuming transplantation eliminates disease risk: Patients and providers must understand that IgAN can and often does recur
- Inadequate post-transplant surveillance: Protocol biopsies may be needed to detect early recurrence before significant graft damage occurs 7
- Delayed treatment of recurrence: Early intervention when recurrence is detected may preserve graft function 7
- Ignoring pre-transplant disease activity: Patients should ideally have optimized disease control before transplantation 10
The Bottom Line
Kidney transplantation provides superior quality of life and survival compared to dialysis for patients with kidney failure from IgAN 11. However, it replaces kidney function rather than curing the underlying disease. The persistent risk of recurrence, associated with substantial graft loss, necessitates lifelong monitoring and often requires ongoing disease-specific treatment even after successful transplantation 7, 3.